Table 1 Sample characteristics of hospitalized COVID-19 patients (N = 242)
From: Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes
| Â | Median (SD) or % (n) |
|---|---|
Age (years) | 63.5 (13.1) |
Male | 58.7 (142) |
Ancestry | |
 African | 42.6 (103) |
 European | 41.7 (101) |
 Other or unreported | 15.7 (38) |
Tobacco use (ever) | |
 No | 39.7 (96) |
 Yes | 32.6 (79) |
 Unknown | 27.7 (67) |
BMI (> 30 kg/m2) | 50.4 (122) |
Diabetes | 60.7 (147) |
History of malignancy | 18.2 (44) |
COVID-19 mortality (40Â days) | 18.6 (45) |
COVID-19 mortality (100Â days) | 22.7 (55) |
Pulmonary disease | 23.1 (56) |
Cardiovascular disease | 41.3 (100) |
Chronic kidney disease (eGFR < 60) | 30.2 (73) |
CH (VAF ≥ 2.0%) | |
 Overall | 23.6 (57) |
 DNMT3A dominant | 14.5 (35) |
CH (VAF ≥ 5.0%) | |
 Overall | 11.6 (28) |
 DNMT3A dominant | 6.6 (16) |